Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation typeRoberto Buonaiuto, Carmine De Angelis, Giancarlo Troncone et al.|Frontiers in Oncology|2024Cited by 9
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysisRoberto Buonaiuto, Carmine De Angelis, Mario Fordellone et al.|EClinicalMedicine|2025Cited by 7
Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysisRoberto Buonaiuto, Michelino De Laurentiis, Aldo Caltavituro et al.|The Breast|2024Cited by 4
Abstract P4-11-08: Comparative analysis of clinician and AI decision making in HR+/HER2- early breast cancerRoberto Buonaiuto, Mario Giuliano, Aldo Caltavituro et al.|Clinical Cancer Research|2025Cited by 1
Efficacy and Safety of Systemic Therapies Following Progression on CDK4/6 Inhibitors in Patients with HR+/HER2-- Metastatic Breast Cancer: A Systematic Review and Network Meta-AnalysisRoberto Buonaiuto, Carmine De Angelis, Mario Fordellone et al.|SSRN Electronic Journal|2025Cited by 0